Dupilumab in type 2 airway inflammation-a step forward in targeted therapy for COPD.

<p>Chronic obstructive pulmonary disease (COPD) is characterized by persistent symptoms and airflow limitation due to a combination of small airway obliteration and alveolar destruction.<a href="https://www.sciencedirect.com/science/article/pii/S0091674923013957?via=ihub#bib1" target="_blank">1</a> Underpinning its diverse nature and phenotypic heterogeneity is a complex interplay of genetics, lung development, dysanapsis, and environmental exposures, in particular cigarette smoking, over time.<a href="https://www.sciencedirect.com/science/article/pii/S0091674923013957?via=ihub#bib1" target="_blank">1</a> The adoption of precision medicine in fields such as asthma has spurred efforts in phenotyping and endotyping COPD to guide management. </p>